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ABSTRACT 
 12-lipoxygenase (12-LOX) is one of several enzyme isoforms responsible for the 
metabolism of arachidonic acid and other poly-unsaturated fatty acids to both pro- and anti-
inflammatory lipid mediators.  Mounting evidence has shown that 12-LOX plays a critical role in 
the modulation of inflammation at multiple checkpoints during diabetes development.  Due to 
this, interventions to limit pro-inflammatory 12-LOX metabolites either by isoform-specific 12-
LOX inhibition, or by providing specific fatty acid substrates via dietary intervention, has the 
potential to significantly and positively impact health outcomes of patients living with both type 1 
and type 2 diabetes.  To date, the development of truly specific and efficacious inhibitors has 
been hampered by homology of LOX family members; however, improvements in high 
throughput screening have improved the inhibitor landscape.  Here, we describe the function 
and role of human 12-LOX, and mouse 12-LOX and 12/15-LOX, in the development of diabetes 
and diabetes-related complications, and describe promise in the development of strategies to 
limit pro-inflammatory metabolites, primarily via new small molecule 12-LOX inhibitors. 
 
 
Keywords:  lipoxygenase, type 1 diabetes, type 2 diabetes-related complications, inflammation, 
lipoxygenase inhibitors 
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Abbreviations: 
LOX:  lipoxygenase (12-LOX, 15-LOX, 12/15-LOX, etc., are isoforms of lipoxygenase) 
PUFA:  poly-unsaturated fatty acids 
AA:  arachidonic acid 
COX:  cyclooxygenase 
DHA:  docosahexaenoic acid 
12(S)-HETE:  12-S-Hydroxyeicosatetraenoic acid (also 15-S-HETE isoform) 
HTS:  High throughput screening 
CDC:  Cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate 
PIC:  pro-inflammatory cytokines 
ROS:  reactive oxygen species 
ER:  Endoplasmic reticulum 
NOX-1:  NADPH Oxidase-1 
IL-12:  Interleukin-12 
IL-1β:  Interleukin-1 beta 
TNF-α:  Tumor necrosis factor-alpha 
IFN-γ:  Interferon-gamma 
IL-6:  Interleukin-6 
MCP-1:  Monocyte chemoattractant protein-1 
TGF-β:  Transforming growth factor-beta 
STAT4:  Signal transducer and activator of transcription 4 
T1D:  type 1 diabetes 
T2D:  type 2 diabetes 
STZ:  streptozotocin 
NOD:  Non-obese diabetic mouse  
Alox15:  mouse Alox15 gene that encodes 12/15-LOX 
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NK:  Natural killer cell 
WT:  Wild-type 
pLOKO:  Pdx1-Cre-mediated deletion of Alox15  
Pdx1:  Pancreatic and duodenal homeobox 1 
HFD:  High Fat Diet 
CCL2:  C-C Chemokine Ligand 2  
CTLA4-Ig: cytotoxic T-lymphocyte-associated protein 4- immunoglobulin 
AT:  Adipose Tissue 
WAT:  White Adipose Tissue 
DIO:  Diet-induced Obesity 
SVF:  Stromal vascular fraction 
DR:  Diabetic retinopathy 
DN:  Diabetic nephropathy 
DPN:  Diabetic peripheral neuropathy 
NAFLD:  Non-alcoholic fatty liver disease 
NASH:  Non-alcoholic steatohepatitis 
CVD:  Cardiovascular disease 
SC:  Subcutaneous fat 
OM:  Omental fat 
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1.  Introduction:   
 The lipoxygenase (LOX) family of enzymes is represented across multiple species, from 
plants to mammals (Kuhn et al., 2015).  In humans, 6 family members have been sequenced 
and characterized.  Seven members have been described in mice.  These enzymes are 
responsible for the metabolism of poly-unsaturated fatty acids (PUFAs) to form functionally 
active metabolites that act in an autocrine, paracrine, and endocrine manner.  The diversity in 
the function across this family of enzymes (Table 1) has frequently led to confounding results, 
which are only recently beginning to be clarified. In this review, we will discuss the tissue 
specific roles of various lipid metabolites produced by 12-LOX (gene product of ALOX12), that 
contribute to the progression of diabetes and co-morbidities. We will also discuss the functional 
role of mouse 12/15-LOX (the gene product of mouse Alox15), in diabetes and complications 
related to diabetes, as various rodent models have been used to generate proof-of-concept 
evidence for pathogenicity of this pathway. Focused discussion on the effects of pro-
inflammatory 12-LOX metabolites, such as 12-hydroxyeicosatetraenoic acid (12(S)-HETE) on 
beta cells, adipocytes, immune cells, vascular cells, and hepatocytes will highlight the functional 
complexities and opportunities for intervention. Understanding the impact of inflammatory 12-
LOX metabolites on the intracellular events involved in the transition from functional to 
dysfunctional beta cells could offer new approaches to preserve beta cells exposed to 
inflammation. Similarly, interventions to limit pro-inflammatory effects in adipose tissue and liver, 
as well as the vasculature and kidney, could positively impact on outcomes for diabetes co-
morbidities. Recent therapeutic opportunities using selective and potent 12-LOX isoform 
inhibitors will be critically discussed in the context of type 1 and type 2 diabetes onset and 
progression.  
 
Biochemistry of 12-LOX 
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12-LOX is an oxygenase that generates a hydroperoxide product by inserting an oxygen 
molecule into a 1,4-diene of PUFAs (Kuhn et al., 2015; Yeung and Holinstat,2011), which is 
subsequently reduced to its alcohol by glutathione peroxidase 4 (Imai et al., 1998; Schneider et 
al., 2010). Numerous PUFAs serve as substrates for 12-LOX, including arachidonic acid (AA), 
dihomo-γ-linoleic acid, docosahexaenoic acid (DHA), and eicosapentaenoic acid (Ikei  et al.. 
2012). Notably, the promiscuity of 12-LOX activity results in the generation of oxylipin products 
from 12(S)-HETE to Maresin 1, with a wide breadth of biological activity (Serhan and Petasis, 
2011). Another aspect of 12-LOX that is notable is its product selectivity. For example, with AA 
as the substrate, 12-LOX produces one stereo-isomer,12(S)-HETE; however, the related family 
member, 12/15-LOX (ALOX15 gene in humans), is less selective and produces 90% 15(S)-
HETE and 10% 12(S)-HETE (Ivanov et al., 2010). Both 12- and 15- LOX metabolites can have 
pro-inflammatory effects in humans. To mechanistically dissociate the effects of the 12- and 15-
LOX pathways and their respective metabolites is crucial to understanding how these pathways 
function in human disease. To further clarify the particular role of these products in disease, 
specific pharmacologic inhibitors for each of the LOX isoforms were developed, and will be 
discussed later in the review.   
Species similarities: rodent versus human 
 The development pipeline for enzymatic inhibitors frequently uses mouse models to test 
safety and efficacy of potential inhibitors.  Therefore, understanding the structural and functional 
relationships between human and mouse lipoxygenases is key in this process.  Human and 
mouse platelet 12-LOXs share 85% sequence homology. More importantly, they are similar in 
their reactivity, with both producing only 12(S)-HETE. In comparing different human isoforms, 
however, human 15-LOX1 shares only 65% sequence homology to human 12-LOX.  It should 
be emphasized that for lipoxygenases, specific active site residues have dramatic effects on 
product production, and therefore, whole protein sequence identity should be viewed with 
caution. For example, human ALOX15 product, 12/15-LOX, produces 90% 15(S)-HETE and 
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10% 12(S)-HETE, while mouse 12/15-LOX produces 90% 12(S)-HETE and 10% 15(S)-HETE, 
despite 73% sequence homology. Therefore, even though the two proteins originate from the 
homologous gene family, they do not produce the same oxylipins.  These factors must be 
addressed during the development and selection of potential enzymatic inhibitors of 
lipoxygenase family members.  Special emphasis based on recent data was on preventing 
production of 12(S)-HETE that was shown to have a multitude of pro-inflammatory effects in 
different cells and tissues, as discussed throughout this review. 
2.  Approaches for 12-LOX and 15-LOX inhibition 
Rationale for 12-LOX and 15-LOX Inhibition 
 Lipoxygenase activation is an important component of inflammation, possibly having 
greater relevance for chronic inflammatory responses. In recent years, the contribution of 
chronic inflammation has been recognized as a significant component to the underlying 
pathology of several major diseases, including diabetes. Increased 12/15-LOX activity has been 
implicated as a contributing factor in the development of both atherosclerosis and diabetic 
neuropathies (Wen et al., 2007; Nagelin et al., 2008; Stavniichuk et al., 2010).  Activation of 
macrophages by 12/15-LOX, and activation of downstream cytokine and chemokine pathways 
contribute to these chronic inflammatory processes. Thus, great interest has been applied to the 
identification of selective and potent inhibitors of lipoxygenase enzymes, specifically 12/15-LOX.   
Efforts have been based on classic quantitative high-throughput screening (HTS) supported by 
medicinal chemistry, computational chemistry and natural product isolation.   
 12-LOX and 15-LOX inhibitors – a historical perspective 
In general, LOX inhibitors are relatively easy to discover, with numerous publications of 
new inhibitors being produced monthly. This is due, in part, to the fact that there are a variety of 
approaches to generate inhibitors of different classifications, such as redox, iron chelating, 
suicide, allosteric, and competitive. However, few of the numerous LOX inhibitors discovered 
are specific to a particular human LOX isozyme, and even fewer target human platelet 12-LOX. 
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Specifically inhibiting 12-LOX, and not the other LOX isozymes, is important because each LOX 
isozyme has a specific biosynthetic role in human inflammatory responses (Serhan and Petasis, 
2011), and therefore, utilizing non-specific LOX isozyme inhibitors would confound biological 
interpretation, and possibly result in drug safety consequences due to off-target effects. For 
example, baicalein, (Deschamps et al., 2006) caffeic acid (Cho et al., 1991; Doiron et al., 2017), 
and the caffeic acid derivative, Cinnamyl-3,4-dihydroxy-alpha-cyanocinnamate (CDC) (Pergola 
et al., 2011), were initially thought of as a specific 12-LOX inhibitors, but were later proven to be 
non-specific.  This creates a challenge for the biochemists trying to generate and characterize 
specific inhibitors.   
Initially, the only 12-LOX selective inhibitors were obtained from natural sources. The 
most significant by far is hinokitiol, whose potency is sub-micromolar (IC50 = 0.1) and its 15-
LOX-1/ 12-LOX (15/12) ratio is approximately 500 (Suzuki et al,. 2000). Unfortunately, hinokitiol 
was found to be cytotoxic and teratogeneic in living tissue (Inamori et al., 1993). Other natural 
products were also shown to be selective, such as bromophenols (15/12 ratio = 5) (Segraves, et 
al., 2004) and isoflavanones (15/12 ratio = 26) (Vasquez-Martinez et al., 2007), but they were 
not potent enough for drug discovery. HTS was also applied to finding potent/selective 12-LOX 
inhibitors with mixed results. Our initial screen found potent/selective molecules, but they did not 
fulfill the drug-like qualities (Deschamps et al., 2007). A subsequent HTS produced an 8-
hydroxyquinoline (ML127), which was both potent (IC50 = 0.4 uM) and selective (100-fold less 
active against both other LOX and COX isozymes, Figure 1) (Kenyon et al., 2011). However, 
ML127 is metal chelator, which raises the specter of off-target effects, lowering its appeal as a 
drug candidate. From the same HTS, a benzenesulfonamide was discovered (ML355, Figure 
1), whose structure was much more “drug-like.” Its potency was sub-micromolar (IC50 = 0.3 
uM), and its selectivity was greater than 100-fold higher compared to both other LOX and COX 
isozymes (Luci et al., 2014). More importantly, ML355 showed cellular potency in human 
platelets and mouse bleed models (Tourdot and Holinstat, 2017). ML355 is currently the state-
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of-the-art for potent/selective 12-LOX inhibitors, and is an appropriate molecule for 12-LOX 
biological studies.  
A brief mention should be given to the specific human 12/15-LOX inhibitor ML351, which 
has the ability to inhibit mouse 12/15-LOX (Figure 1) (Rai et al., 2014). This is noteworthy 
because mouse 12/15-LOX (encoded by the Alox15 gene) produces primarily 12(S)-HETE, 
while human 15-LOX1 produces primarily 15-HETE, as discussed above. This result indicates 
their active sites are distinct; however, ML351 inhibits them both. As will be discussed later in 
this review, this ability to inhibit mouse 12/15-LOX is important in the pre-clinical study of 
diabetes due to the involvement of 12/15-LOX in mouse models of diabetes, but not in human 
diabetes.  These differences in mouse versus human enzymatic activity have led to difficulties in 
testing inhibitors, and developing the translational pipeline.  As will be discussed later in this 
review, the ability of inhibitors, such as ML351, to inhibit mouse 12/15-LOX is important for 
proof-of-concept mechanistic studies in mouse models of diabetes. In comparing ML355 and 
ML351 (Figure 1), one can observe their chemical structures are very distinct. ML351 is an 
amine oxazole, while ML355 is a benzenesulfonamide. These structural differences present 
distinct chemical surfaces that lead to their LOX selectivity. 
3.  12-LOX and 12/15-LOX pathogenic roles and their inhibition and pancreatic beta cells 
 The relationship of 12/15-LOX activation to the development of diabetes has been 
validated in genetic deletion studies (Bleich et al., 1999; McDuffie et al., 2008), where global 
deletion of 12/15-LOX led to significant protection (>98%) from diabetes development in both 
the streptozotocin (STZ) and spontaneous non-obese diabetic (NOD) mouse models. The 
application of the selective human and mouse 12/15-LOX inhibitor, ML351, and the human and 
mouse 12-LOX inhibitor, ML355, has facilitated dissection of the contribution of these pathways 
to inflammation-mediated beta cell dysfunction. Exposure of beta cell lines and primary islets to 
pro-inflammatory cytokines (PIC; TNF-α, IL-1β, IFN-γ) results in compromised beta cell function 
and survival. The effects of PICs can be reproduced with direct addition of 12-HETE, (Ma et al., 
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2010). This implied role for 12-LOX and 12/15-LOX activation as a mediator of beta cell 
dysfunction was validated with the use of ML127/ML355 selective inhibitors. With inclusion of 
either ML127 or ML355, markers of beta cell function and survival were preserved in the 
presence of PICs (Luci et al., 2014; Taylor-Fishwick et al., 2015). Furthermore, protection with 
ML127/ML355 was seen in homogeneous beta cell lines and primary human islets (Ma et al., 
2017; Taylor-Fishwick et al., 2015). Such a strategic approach would slow the progression of 
diabetes as mono-therapy, or reverse diabetes as a combinatorial therapeutic approach when 
coupled with an islet regeneration strategy.  This could be utilized in either endogenous beta cell 
stimulation or exogenous repopulation (cell transplantation/encapsulation/xenotransplantation 
etc.). 
  
12/15-LOX and oxidative stress in beta cells 
 As mentioned above, 12/15-LOX activation contributes to islet demise.  Pro-
inflammatory cytokines potently induce cellular reactive oxygen species (ROS). Relative to other 
cells, beta cells exhibit a lower activity of free-radical detoxifying enzymes, including catalase, 
superoxide dismutase, and glutathione peroxidase.  Consequently, beta cells are predisposed 
to oxidative stress (Lenzen, 2008). Sources of ROS in the beta cell include induced 
mitochondrial stress (Newsholme et al., 2007), endoplasmic reticulum (ER) stress (Volchuk and 
Ron, 2010), and recently recognized NADPH oxidase activation (Taylor-Fishwick, 2013).  Pro-
inflammatory cytokines induce NADPH oxidase-1 (NOX-1) and elevate intracellular ROS in beta 
cells. Studies that modulate NOX-1 activity support an important role for NOX-1 in beta cell 
pathology. Selective inhibition of NOX-1 preserves beta cell function and islet survival (Weaver 
et al., 2015; Weaver and Taylor-Fishwick, 2017; Weaver et al., 2015a).  
 Lipid mediators have been linked with the activation of NOX. Two products of 
phospholipase A2 (PLA2) activity, arachidonic acid (AA) and lysophosphatidic acid (LPA) are 
involved in direct interaction with and activation of the NOX complex, principally the NADPH 
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oxidase isoenzyme NOX-2 (Matono et al., 2014; Ha et al., 2018). While the importance of this 
interaction is clear, the exact activation pathways linking lipid mediators and NOX activation is 
far from resolved. Previous studies are often limited by data derived using non-specific inhibitors 
of NOX, and numerous downstream enzymes and bioactive metabolites in the eicosanoid 
pathway (cyclooxygenase, lipoxygenase, leukotrienes etc.) activate NOX in a variety of 
experimental cell systems (reviewed in Cho et al., 2011). 
 An association between the 12/15-LOX pathway and NOX-1 pathway has been 
investigated in beta cell lines and islets (Weaver et al., 2012). Direct addition of 12(S)-HETE to 
beta cells induced NOX-1 expression. Conversely, inhibition of 12/15-LOX activity blocked 
NOX-1 upregulation mediated by pro-inflammatory cytokines (Weaver et al., 2012). 12/15-LOX 
inhibition also reduced elevation of ROS in beta cells stimulated with pro-inflammatory 
cytokines. These data help integrate intracellular events in the beta cell exposed to 
inflammation.  
12/15-LOX and interleukin-12 in pancreatic islets and beta cells  
 Beta cells are not only extremely susceptible to inflammatory damage, but they also 
have the ability to produce inflammatory cytokines.  Identification of interleukin-12 (IL-12) 
production and function in beta cells presents a further integration of 12/15-LOX (Taylor-
Fishwick et al., 2013). A consequence of PIC-stimulation in beta cells and primary islets is the 
production of IL-12, which facilitates an escalating loop of inflammation.  
 Beta cells, including human beta cells, express the receptor for the IL-12 ligand and are 
responsive to IL-12-ligand/IL-12-receptor ligation. Administration of exogenous IL-12 directly 
mediates beta cell dysfunction (Taylor-Fishwick et al., 2013). Exogenous IL-12 induces a dose 
dependent expression of IFN-γ in beta cell lines, suggesting a functional IL-12/STAT4/IFN-γ 
axis. Previous studies describe STAT4 signaling in islet beta cells (Yang et al., 2004; Yang et 
al., 2003). Additionally, selective inhibition of the IL-12/STAT4 axis in beta cells, utilizing multiple 
strategies of inhibition, preserves beta cell survival in the presence of PICs (Weaver et al., 
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2015b). Neutralization of IL-12 with an IL-12 antibody blocked beta cell dysfunction induced by 
PIC stimulation (Taylor-Fishwick et al., 2013), and functional defects in beta cells mediated by 
IL-12 correlate with those seen following PIC stimulation. Both receptor and ligand for IL-12 are 
upregulated in beta cells exposed to PIC stimulation. These studies suggest that pro-
inflammatory cytokines induce local IL-12 expression that may be a mediator of PIC-induced 
beta cell dysfunction. Inhibitors of 12/15-LOX suppress the induction of IL-12 ligand in islets and 
beta cells exposed to PIC. Pro-inflammatory cytokine stimulation of 12/15-LOX activity is implied 
in the regulation of beta cell IL-12 production. 
 The mechanisms by which 12/15-LOX activation leads to IL-12 production will require 
additional investigation; however, ROS production has been linked to IL-12 production (Aramaki 
et al., 2002).   In beta cells, activation of NOX-1, subsequent to 12/15-LOX, could be the 
intermediary step to the production of ROS that regulates IL-12 production in beta cells following 
exposure to PICs.  Given the impact of 12/15-LOX activity on beta cells, it is not surprising that 
this enzyme plays a critical role in the development of both type 1 and type 2 diabetes (T1D and 
T2D, respectively), and also contributes to the development of diabetic complications. The 
development of potent and specific 12/15-LOX inhibitors has the potential to significantly alter 
the landscape of therapeutics in diabetes.   
4.  12-LOX and 12/15-LOX in T1D 
Role of 12/15-LOX in islet and immune cell types in T1D 
Historically, T1D has been characterized as an autoimmune disease that is initiated and 
perpetuated by autoreactive T cells.  Despite the historical emphasis on the T cell response, 
mounting evidence suggests that inflammatory damage to islets and innate immune cells also 
contribute to disease development (Maganti et al., 2014).   
Since both islets and innate immune cells are capable of expressing activated 12/15-
LOX, it is not unreasonable to think that these two cell types might interact to contribute to T1D 
development.  A potential causative role for 12/15-LOX in T1D pathogenesis was first 
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suggested nearly twenty years ago (Bleich et al., 1999), when it was shown that mice deficient 
for the gene encoding 12/15-LOX on the C57BL/6J background were protected from developing 
diabetes in the multiple low-dose STZ model of T1D.  This research led to the subsequent 
development of NOD congenic mouse lines in which the Alox15 gene was deleted globally 
(McDuffie et al., 2008). In the absence of 12/15-LOX, NOD mice are significantly protected from 
spontaneous diabetes development, with only ~3% of mice developing disease by 30 weeks of 
age (compared to average rates of 60-80% spontaneous diabetes development in wild-type 
NOD mice).  Notably, there was a significant decrease in the numbers of macrophages in the 
islets of mice at 4-5 weeks of age, a time point that precedes the development of T cell-
mediated insulitis in the NOD strain.  Further characterization of these mice showed that 
whereas both islets and macrophages produce 12/15-LOX, adaptive immune cells (B cells and 
T cells) do not.  Characterization of both islets and macrophages from Alox15-deficient NOD 
mice demonstrated decreased pro-inflammatory phenotypes (Green-Mitchell et al., 2013). Both 
islets and macrophages from Alox15-deficient mice exhibit reduced expression of the genes 
encoding pro-inflammatory cytokines IFN-γ, IL-12, TNF-α, and IL-1β.  Furthermore, islets in 
Alox15-deficient NOD mice have increased beta cell mass prior to the onset of insulitis.  Taken 
together, these data suggest that 12/15-LOX likely contributes directly to both beta cell 
dysfunction and loss, as well as macrophage activation (Figure 2).  12/15-LOX deficiency does 
not appear to affect the general health of the mice, suggesting that targeting the activity of this 
enzyme may be a safe and viable therapeutic option.   
To test more directly the role of 12/15-LOX in the pancreatic islet, a Cre-lox strategy was 
utlilized to delete Alox15 in islets using the Pdx1-Cre deleter strain on the C57BL/6J mouse 
background (Tersey et al., 2014).  In this model, islet-specific deletion of 12/15-LOX led to 
protection from multiple low-dose STZ-induced diabetes, a phenotype that is virtually identical to 
the whole-body Alox15 knockout mice (Bleich et al., 1999). Recently, use of a 12/15-LOX 
inhibitor (ML351) in the NOD mouse model was shown to preserve beta cell mass and function, 
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and to reduce insulitis and hyperglycemia (Hernandez-Perez et al., 2017). Interestingly, 
although these findings were attributed to the effects of 12/15-LOX inhibition in the beta cell, it 
was also observed that the nature of the remaining islet infiltrate was altered, with greater 
presence of alternatively activated (M2) macrophages.  Therefore, these results suggest the 
possible contribution of 12/15-LOX to both beta cell function and inflammatory cell phenotypes.  
Studies to date have not fully resolved the contributions of the individual cell types.  To address 
the specific role of 12/15-LOX in beta cells versus innate immune cells, targeted deletion Cre-
lox strategies on the NOD background are being pursued.   
Although adaptive immune cells do not express detectable levels of 12/15-LOX, natural 
killer (NK) cells express surprisingly high levels of 12/15-LOX (Semeraro et al., 2017).  NK cells 
from congenic Alox15-deficient NOD mice display significantly higher levels of stimulatory 
receptors on their surface as compared to wild-type NOD NK cells (Semeraro et al., 2017), a 
finding that correlates with results seen in non-diabetic human NK cells as compared to those 
from donors with T1D  (Qin et al., 2011).  NK cells not only have the capacity to interact with 
macrophages, but also with pancreatic beta cells, giving them the potential to play a multi-
faceted role in T1D development.   
Role of 12-LOX in human T1D 
Translationally, human 12-LOX has been implicated in the pathogenesis of human T1D.  
Recent studies (Hennessy et al., 2017)  have shown that individuals with recent-onset T1D 
exhibit elevations in the circulation of the major pro-inflammatory product of 12-LOX, 12(S)-
HETE, raising the possibility of a causative correlation between the 12-LOX pathway and T1D 
pathogenesis.  Isolated human islets treated with PIC expressed elevated levels of 12-LOX (Ma 
et al., 2010). PIC treatment under these conditions is thought to mimic the response of islet beta 
cells to autoimmune attack in T1D (Figure 2).  These results correlate well with the protein 
expression of 12-LOX in pancreatic sections obtained from human donors, which revealed that 
islets only express 12-LOX under systemic inflammatory conditions, including cases of pre-T1D 
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(autoantibody positive), early T1D, and T2D (Grzesik et al., 2015). In this study, it was noted 
that expression of 12-LOX dissipates once endogenous insulin production is abolished, possibly 
as a result of beta cell dedifferentiation.  Although convincing evidence points towards a key role 
for 12/15-LOX metabolites at the onset of T1D, there is no evidence showing how such 
metabolites may change during interventions designed to address the underlying pathology of 
T1D, apart from insulin treatment, such as anti-CD3, selective tyrosine kinase inhibitors 
(Gleevec), or CTLA4-Ig. Such studies using immunologic approaches should be a valuable 
source of information for revealing changes in the 12-LOX metabolites that may further support 
the contention that 12-LOX pathway is directly related to the immune-mediated mechanisms in 
type 1 diabetes. 
5.  12-LOX and 12/15-LOX in T2D 
Role of 12/15-LOX in islet dysfunction using mouse models of T2D 
 The first evidence that 12/15-LOX in pancreatic islets contributed to the development of 
T2D was obtained in a diet-induced obese (DIO) mouse model with a germline deletion of the 
12/15-LOX (Alox15 gene) (Nunemaker et al., 2008). The Alox15 deficient mice on Western diet 
maintained glucose tolerance at the levels similar to wild type (WT) C57BL/6 mice fed a normal 
chow. Improved glucose tolerance in Western diet-fed Alox15-deficient mice compared to WT 
controls was due in part to reduced adipose tissue inflammation, but also likely due to improved 
islet function.  12(S)-HETE levels, were increased in the islets of Western diet-fed WT mice 
compared to Alox15-deficient mice. In addition, islets of Alox15 deficient mice showed higher 
glucose-stimulated insulin secretion and decreased apoptosis compared to islets from WT mice 
on Western diet (Nunemaker et al., 2008).   
 To further define the contribution of 12/15-LOX in the development of islet dysfunction in 
T2D, glucose homeostasis and islet function were assessed in high fat fed mice with Pdx1-Cre 
mediated deletion of Alox15 (pLOKO) (Tersey et al., 2014). Of note, the expression of Alox15 in 
exocrine pancreas is minimal, and therefore, pLOKO mice provide a means to elucidate the 
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contribution of islet 12/15-LOX.  pLOKO mice became insulin resistant on high fat diet (HFD), 
similar to their HFD-fed WT littermates; however, their glucose tolerance was better and insulin 
secretion was higher than in WT mice on HFD. In addition, pLOKO mice on HFD had increased 
beta cell area compared with WT mice on HFD, indicating a better compensatory increase in 
beta cell mass in the absence of islet 12/15-LOX. The islets from WT mice showed increase in 
markers of oxidative stress, ER stress, and beta cell death.  In contrast, these parameters were 
lower in pLOKO mice. The upregulation of antioxidant genes (SOD, Gpx1, catalase) by the 
activation of the Nrf 2 transcription factor was implicated as a mechanism by which islets of 
pLOKO showed better adaptation to HFD (Tersey et al., 2014). In the db /db model of T2D, both 
forms of 12/15-LOX are expressed in islets (12-LOX and 15-LOX).  The islet 12/15-LOX 
increase parallels the decline in beta cell mass (Dobrian et al., 2018). Collectively, studies 
conducted in mouse models of T2D strongly support the causal relationship between 12/15-LOX 
activity and beta cell dysfunction in T2D.  
Role of 12-LOX in beta cell dysfunction in humanT2D 
 There is evidence that 12-LOX is elevated in human islets during the development of 
T2D. 12-LOX expression, tested by immunofluorescence, is increased in islets of some T2D 
donors, along with T1D and autoantibody positive donors (Grzesik et al., 2015).  Furthermore, 
human islets isolated from donors with T2D also showed higher expression of 12-LOX than 
islets from non-diabetic donors (Butcher et al., 2014). When glucose stimulated insulin secretion 
was examined, T2D islets expressing high levels of ALOX12 mRNA had a reduced, but 
detectable response to glucose compared with islets from non-diabetic donors. In contrast, the 
expression of pro-inflammatory genes CCL2 and TNFA, but not ALOX12, were increased in 
T2D islets that showed blunted response in insulin secretion in response to glucose. 
Considering that 12-LOX disappears once endogenous insulin supplies are exhausted in T1D 
islets (Grzesik et al., 2015), the up-regulation of 12-LOX in islets with mild to moderate 
impairment in insulin secretion in T2D may reflect active involvement of 12-LOX in stressed beta 
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cells prior to beta cell loss or dedifferentiation in T2D. Importantly, the inhibition of 12-LOX with 
ML-355 was shown to improve the function of human islets from type 2 diabetic donors (Ma et 
al., 2017). 24-hour treatment of human islets from type 2 diabetic donors with the 12-LOX 
inhibitor ML355 improved glucose-stimulated insulin secretion and oxygen consumption rate 
compared with vehicle treated islets from the same donors. Thus, the activation of 12-LOX 
appears to contribute to the reduction of functional beta cell mass in both T1 and T2D, and the 
inhibition of 12-LOX may prevent the progression of beta cell loss in both forms of diabetes.   
Role of 12-LOX and 12/15-LOX in adipose tissue in obesity and T2D 
 Type 2 diabetes is associated with obesity and insulin resistance. These conditions 
impact heavily on the physiology of adipose tissue. In obesity, adipose tissue (AT) is 
characterized by a state of low grade inflammation that alters the metabolic performance of 
adipocytes, and can indirectly or directly impact on metabolism and inflammation in the liver and 
skeletal muscle. AT inflammation is now considered a hallmark of obesity and insulin resistance 
(Figure 3).  The remarkable cellular complexity and plasticity of this tissue implies multi-faceted 
roles for various inflammatory pathways that are usually operational in more than one cell type, 
and are causatively associated with both persistence or resolution of inflammation (Cole et al., 
2013). There is emerging evidence that the various 12/15-LOX isoforms in both white (WAT) 
and brown fat are expressed in multiple cell constituents of AT, and their metabolites may have 
either pro- or anti-inflammatory effects in a cell-specific and temporal manner (Lopategi et al., 
2016).   
 Evidence for the pro-inflammatory role of 12/15-LOX in adipocytes emerged from proof 
of concept pre-clinical models of genetic or diet-induced obesity (DIO), insulin resistance, and 
type2 diabetes. As described above, 12/15-LOX knockout mice are protected from developing 
insulin resistance in DIO (Nunemaker et al., 2008).  In DIO C57Bl/6J mice, high fat diet is 
accompanied by increased 12/15-LOX expression and activity in adipose tissue and white 
epididymal adipocytes (Nunemaker et al., 2008; Sears et al., 2009; Chakrabarti et al., 2009).  
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Zucker obese rats, a genetically-induced model of obesity and insulin resistance, also exhibit 
increased expression of 12/15-LOX in isolated white adipocytes compared to lean controls 
(Chakrabarti et al., 2011).  Also, more recent data from our lab showed that both 12/15-LOX and 
12-LOX are present in AT and adipocytes from db/db mice, and they undergo expressional 
increases that coincide with the metabolic decline (Dobrian, et al., 2018).   
 To confirm a direct role of 12/15-LOX activity in mediating inflammation and insulin 
resistance in adipocytes, the effect of 12(S)-HETE, the major 12/15-LOX metabolite in mouse, 
was examined in 3T3-L1 adipocytes by Chakrabarti et al.(Chakrabarti et al., 2009).  Addition of 
both 12(S)-HETE and its precursor, 12(S)-hydroperoxyeicosatetraenoic acid, to fully 
differentiated 3T3-L1 adipocyte cultures significantly induced pro-inflammatory gene expression, 
and secretion of many pro-inflammatory cytokines, including TNF-, MCP-1, IL-6, and IL-12p40. 
Adipocyte dysfunction is not only marked by chronic inflammation and insulin resistance of 
WAT, but also by ER stress (Boden, 2009). Evidence from our lab demonstrates that 12/15-LOX 
is a novel inflammatory pathway that mediates ER stress in adipocytes (Cole et al., 2012a). To 
further confirm that adipocyte-derived 12/15-LOX plays a key role in obesity-induced insulin 
resistance, our lab has generated a 12/15-LOX adipocyte-specific germline deficient mouse that 
displayed reduced AT inflammation and macrophage infiltration into the epididymal WAT (Cole 
et al., 2012b).  Interestingly,  inflammation in the pancreatic islet was also reduced in the high-
fat diet-fed 12/15-LOX fat-specific-deficient mice compared to WT controls (Cole et al., 2012b).  
These data suggest a crosstalk between 12/15-LOX expression in WAT and inflammation in 
pancreatic tissue, revealing a considerable systemic impact of chronic 12/15-LOX activation in 
AT in DIO.  Much less is known about the contribution of AT macrophage-derived 12/15-LOX.  
 Analysis of AT and the corresponding stromal vascular fraction (SVF) showed a significant 
increase of 12/15-LOX gene expression along with 12- and 15-HETEs in db/db mice compared to 
heterozygous controls. We found that out of the LOX metabolites measured, 12(S)-HETE was 
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the most abundant one, and was selectively increased in db/db mice in parallel with the decline 
in glycemic control.  
 There is also evidence that the 12/15-LOX pathway may also generate metabolites that 
are key in the resolution of inflammation (Serhan and Chiang, 2008 Serhan et al., 2008a; 
Serhan et al., 2008b). In particular, 12/15-LOX may generate ω-6 PUFAs, such as lipoxins, or 
ω-3 PUFAs, such as maresins, resolvins, and protectins, in conjunction with the 5-lipoxygenase 
and COX enzymes (Chiang et al., 2005; Serhan et al., 2018) (Figure 3). AT dysfunction in 
obesity is likely the result of an inappropriate inflammatory response that remains uncontrolled 
due to intrinsic inability of the tissue for complete resolution of inflammation. The pro-resolving 
metabolites formed as a result of different LOXs may therefore play beneficial effects for limiting 
inflammation in the AT as a result of nutritional overload. A recent publication showed that 
resolvin D1 promotes resolution of AT inflammation in diet-induced obese mice by eliciting 
macrophage polarization toward an M2-like phenotype (Titos et al., 2013). Also, there is 
evidence to suggest that alternatively activated macrophages expressing 12/15-LOX act as a 
sink for distinct soluble receptors for apoptotic cells via the controlled phagocytosis by the 
resident tissue macrophages (Uderhardt et al., 2012). In addition, 3-adrenergic stimulation of 
AT macrophages led to adipocyte apoptosis via induction of 12/15-LOX that resulted in 
production of 9- and 15-hydroxyoctadecadienoic acid.  This further stimulated PPAR and 
adipogenesis (Kwon et al., 2016). A similar mechanism was described for de novo beige/brown 
adipogenesis in rodents (Lee et al., 2016). 
 Interestingly, AT is the major storage site for PUFAs in obese individuals (Lundbom et 
al., 2009). The 12-hydroxy docosahexaenoic acid metabolite, along with protectin D1 and 
resolvin D1, were identified in AT of obese ob/ob mice (Gonzalez-Periz et al., 2009). Recent 
data from our laboratory also showed a variety of both pro- and anti-inflammatory lipid 
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mediators in the SVF of db/db mice, which showed a change in abundance as the mice became 
more glucose intolerant and insulin resistant (Dobrian et al., 2018).  
 There are important differences in the 12/15-LOX pathway between rodents and humans 
(Dobrian et al., 2010a).  We were the first to report 12-LOX mRNA and protein expression in 
human AT, with exclusive localization in the SVF in both the subcutaneous (SC) and omental 
(OM) fat (Dobrian et al., 2010b). In rodents, adipocytes are the abundant source of 12/15-LOX 
(Chakrabarti et al., 2009; Chakrabarti et al., 2011). Increased expression of all 12/15-LOX 
enzyme isoforms in OM versus SC AT suggests that the pathway may contribute to the pro-
inflammatory milieu prominently associated with visceral fat in obesity (Dobrian et al., 2010b).  
Interestingly, in patients with T2D, 12-LOX in particular was up regulated in OM adipose tissue 
suggesting a prominent role in T2D (Dobrian et al., 2010b). 
 Gene array analysis  of AT showed that AA metabolism is the second most significantly 
upregulated pathway in human OM compared to SC AT in obese human subjects, with a 7.6-
fold higher expression of 15-LOX-1 in omental fat (Gealekman et al., 2011). The recent 
discovery of novel metabolites with anti-inflammatory properties, such as DHA-derived fatty acid 
esters of hydroxyl fatty acids (Kuda et al., 2016) or newly characterized oxylipins (Barquissau et 
al., 2017), provides an important therapeutic opportunity to modulate 12/15-LOX activity through 
fatty acid drug discovery (Halade et al., 2018).  
Role of 12/15-LOX in fatty liver development in obesity and T2D  
 Dysregulated adipose tissue function in obesity and T2D also has negative 
consequences in the liver, as both tissues have immediate access to an abundant vascular 
network and can communicate directly via the portal circulation. T2D and obesity are frequently 
associated with non-alcoholic fatty liver disease (NAFLD), as well as the more advanced stages 
of non-alcoholic steatohepatitis (NASH) characterized by irreversible fibrotic changes in the liver 
(Sanyal, 2005; Tilg and Moschen, 2008).  A limited number of studies has investigated the role 
of 12/15-LOX and their metabolites in pathology of liver disease. Similar to other tissues, the 
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substrate availability, the microenvironment, and the relative abundance of different LOX 
isoforms impacts the balance between pro-inflammatory and pro-resolving metabolites. In 
rodent models of DIO-induced steatosis, germline deletion of 12/15-LOX resulted in decreased 
hepatic lipid accumulation, decreased gene expression of TNF- and IFN-, and decreased 
expression of chemokines (Lazic et al., 2014). Similarly, germline deletion of 12/15-LOX 
protected hyperlipidemic Apoe-/- mice from developing NAFLD (Martinez-Clemente et al., 
2010). In a methionine/choline-deficient mouse model of NASH, serum metabolomics showed 
increased levels of 12(S)-HETE along with bile salts compared to a methionine/choline sufficient 
control (Matsubara et al., 2012). These studies suggest that 12/15-LOX contributes to the 
pathogenesis of NAFLD and NASH.  
 Pro-inflammatory metabolites of the LOX pathway may also play a pathogenic role in 
human liver disease. The pro-inflammatory metabolites 5-HETE, 11-HETE, and 15-HETE were 
increased in patients with NASH compared to healthy controls (Puri et al., 2009).  Similar 
findings showed increased 15-HETE levels and higher inflammatory scores in histologic 
sections in the livers of NASH patients (Hall et al., 2017). Finally, a recent study showed an 
important role of 12-LOX/12(S)-HET /GPR31 axis as a mediator of ischemic liver injury in 
ischemia-reperfusion across different species, from mice to rhesus macaques (Zhang et al., 
2018).  
 Studies have also shown the beneficial role of the pro-resolving metabolites in liver 
disease. One recent study showed that protectin DX ameliorated hepatic steatosis in a DIO 
mouse model by suppressing ER stress (Jung et al., 2018). Also, resolvin D1 was shown to 
reduce ER stress-induced apoptosis and triglyceride accumulation in HepG2 cells (Jung et al., 
2014).  Available data suggests that either reducing the dietary 6/3 ratio or inhibiting the 
enzymatic activity of 12/15-LOX may protect against Western diet-induced steatohepatitis. 
6.  12-LOX and 12/15 LOX and Diabetes-related Complications 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 24 
 People with diabetes continue to suffer from high rates of microvascular complications 
such as retinopathy, nephropathy, neuropathy, and from atherosclerotic cardiovascular disease. 
In order to prevent or reduce the damaging effects of these complications, the identification of 
key pathways in disease etiology should be prioritized to foster the development of safe and 
efficacious medications.  Evidence suggests that the 12/15-LOX pathway may contribute to 
these complications. Therefore, further understanding of human relevance of the role of the 
12/15-LOX pathway in diabetes-related complications could lead to the opportunity to develop 
and test specific therapies that include enzyme inhibitors. 
Diabetic retinopathy 
 Diabetic retinopathy (DR) is the leading cause of blindness among working age 
populations, despite the many current treatments to control glycemia in people with diabetes. 
Several new treatments have been developed primarily to target abnormal blood vessel 
development and bleeding (Wang et al., 2018). However, an improved understanding of the role 
of inflammation and relevant molecular pathways could help identify earlier targets for 
prevention and intervention (Wang et al., 2018). Studies have highlighted the role of lipid 
metabolites derived from 12/15-LOX in DR. 12-LOX expression and activity was documented in 
vitreous samples of people with DR (Al-Shabrawry et al., 2011), retina of diabetic mouse models 
(Othman et al., 2013), and human retinal endothelial cells treated with high glucose (Ibrahim et 
al., 2015a). Intravitreal injection of 12(S)-HETE compromises the endothelial barrier in the retina 
leading to inflammatory changes (Ibrahim et al., 2015b).  Recent studies indicate that retinal 
endothelial cells, but not monocytes or macrophages, are key cells linked to 12/15-LOX-related 
retinal effects (Ibrahim et al., 2017). Not all of the effects leading to DR in the capillary bed are 
due to 12/15-LOX, since other studies also suggest a role of 5-LOX (Gubitosi-Klug et al., 2017) 
in the mouse. Additional studies are needed, particularly in human tissues, to clarify the 
particular role and relevance of each LOX isoform as a target for treatment. 
Diabetic nephropathy 
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 Diabetic nephropathy (DN) continues to be a major cause of end stage kidney disease, 
and affects people with type 1 or type 2 diabetes. While elevated glucose plays a key role, 
changes in blood pressure, dysregulation of the renin-angiotensin system (including increased 
activity of angiotensin Type 1 receptor), and dyslipidemia are also important factors. 12(S)-
HETE levels are increased by high glucose and pro-fibrotic factors, such as TGF-β, in kidney 
mesangial cells in vitro (Kang et al., 2001; Reddy et al., 2002; Xu et al., 2006; Xu et al., 2009). 
In addition, 12/15-LOX activation leads to hypertrophy and expression of genes TGF-β and 
angiotensin Type 1 receptor, both of which are closely linked to development of DN (Reddy et 
al., 2002; Xu et al., 2008, Xu, et al. 2009; Zhu et al., 2007; Xu et al., 2016a). 12/15-LOX gene 
deficiency can attenuate TGF-β signaling in mesangial cells (Kim et al., 2003). Use of siRNA to 
reduce 12/15-LOX expression results in a reduction in glomerular dysfunction and in pro-fibrotic 
genes in diabetic mice (Xu et al., 2008; Yuan et al., 2008). A recent study postulates that 12/15-
LOX-derived oxidized lipids modulate pro-fibrotic genes through epigenetic histone 
modifications (Yuan et al., 2016). Given that 12/15-LOX is highly expressed in the kidney and 
expression increases in type 1 or type 2 diabetic models (Kang et al., 2001; Reddy et al., 2002; 
Xu et al., 2009; Guo QY et al., 2011), such a pathway would be a promising target for treatment.  
Indeed, one small molecule inhibitor of 12/15-LOX was shown to reduce proteinuria and renal 
hypertrophy in a type 2 diabetic rat model (Xu et al., 2009). 12/15-LOX activation also can 
induce ROS superoxide anions and lipid peroxidation, which are also involved in advanced 
glycation end products (Kang et al., 2001; Reddy et al., 2002; Brownlee, 2001; Cyrus et al., 
2001; Murea et al., 2010; Natarajan and Nadler, 2004). All of these factors are associated with 
DN. Interestingly, angiotensin receptor blockage, one of the treatments for DN, reduced 12/15-
LOX activation and 12(S)-HETE levels in a diabetic rat model of DN (Xu et al., 2016b). 
Diabetic peripheral neuropathy and other central nervous system disorders  
 Diabetic peripheral neuropathy (DPN) is a very common debilitating complication of T1D 
and T2D. DPN can lead to severe pain, and also is a leading cause of foot amputations. 
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Currently, most approved therapies focus on symptom control, rather than actual disease 
modification.  Therefore, a better understanding of the key pathways linked to development and 
progression of DPN are needed. There is likely a complex interplay between glucose levels, 
genetics, oxidative stress, and inflammation that contribute to DPN, which should be considered 
in the development of new therapeutics.  There is evidence of increased 12/15-LOX expression 
and activity in tissues of experimental animal models of DPN (Stavniichuk et al., 2010; 
Obrosova et al., 2010; Stavniichuk et al., 2012). Pharmacologic inhibition of 12/15-LOX reduced 
p38 and ERK/MAPK activation in mouse sciatic nerve (Stavniichuk et al., 2013). In addition, 
inhibition of 12-LOX reduced glucose-mediated increase in phosphorylation of p38 and 
ERK/MAPK in human Schwann cells, thus suggesting a link between 12-LOX activation and 
DPN in humans (Stavniichuk et al., 2013). The use of the non-specific inhibitor, CDC, gives rise 
to caution in over-interpreting these results. Thus, new more specific and safe inhibitors are 
needed to move these promising pre-clinical studies forward.   
 The impact of 12/15-LOX is not limited to the peripheral nervous system, but also 
appears to play a strong role in the development of several central nervous system diseases.  
Interestingly, the 12/15-LOX pathway has been recently implicated in Alzheimer’s disease (Hur 
et al., 2018; Pratico et al., 2004; Lebeau et al., 2001; Lebeau et al., 2004). There is also 
compelling data for the involvement of 12/15-LOX in brain damage due to stroke (Jin et al., 
2008; Liu et al., 2017; van Leyen et al., 2006; van Leyen et al., 2014; Yigitkanli et al., 2013; 
Yigitkanliet al., 2017).  
Cardiovascular Disease (CVD) 
 People with diabetes continue to have an increased risk of atherosclerotic 
cardiovascular disease. Both inflammatory and anti-inflammatory mediators produced by 12/15-
LOX activation play a complex role in atherosclerotic CVD. Under typical Western Diet 
conditions, it is likely that inflammatory lipids, such as 12(S)-HETE, prevail. The role of 12/15-
LOX metabolites in vascular, renal pathology, and atherosclerosis has been reviewed earlier in 
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great detail (Dobrian et al., 2010a; Imai et al., 2013). More recently, genetic deletion of 12/15-
LOX in mice leads to post-myocardial infarction cardiac protection via augmented cytochrome p-
450-generated, anti-inflammatory epoxyeicosatrienoic acids, and resolving neutrophil 
metabolites (Kain et al., 2018). In particular, reduced myofibroblast formation and collagen 
deposition led to reduced scarring (Kain et al., 2018). A recent report also has indicated that 12-
LOX inhibition can be used as an adjuvant treatment with tissue plasminogen activator (Karatas 
et al., 2018). Platelet activation is a key mechanism in thrombotic disorders such as myocardial 
infarction and stroke. 12-LOX activation potentiates platelet activation and selective 12-LOX 
inhibition decreases thrombosis without prolonging hemostasis (Tourdot and Holinstat, 2017). 
 Thus, 12-LOX and12/15-LOX may be an attractive target to prevent or treat heart failure 
in people with diabetes. More studies using human samples are necessary to clarify the specific 
role of 12-LOX and related products in CVD associated with diabetes.   
7.  Conclusions 
 12/15-LOX isoforms clearly play a role in several key inflammatory aspects related to 
both T1D and T2D, from the initial pathogenic insults through the development of diabetes-
related complications.  Great strides have been made in generating new specific inhibitors that 
target individual LOX family members.  Paired with the use of novel mouse strains in which 
12/15-LOX is deleted in specific tissues, we are poised to significantly increase our 
understanding of the mechanisms underlying these inflammatory processes in diabetes.  
Furthermore, the development of specific inhibitors may prove useful in protecting patients from 
disease progression of diabetes and the accompanying complications.   
The field of T1D is undergoing a renaissance, with questions being raised as to the 
etiology, pathophysiology, and pathology of the disease.  In this context, the role of 12-LOX in 
human disease, with a special emphasis on translational mechanistic opportunities in rodent 
models, becomes especially important.  For example, recent studies suggest a central role of 
viruses in the initiation of the disease, perhaps via signaling through type 1 interferons 
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(Nyalwidhe et al., 2017).  To date, however, the activation of 12/15-LOX through the interferons 
pathway is poorly understood, but clearly requires more study, since it remains possible that 
12/15-LOX may initiate stress pathways within the beta cell that ultimately result in neo-epitope 
formation and autoimmunity.  Similarly, a role for macrophages and innate immune cells in early 
T1D has been appreciated recently, and as such, the role of 12/15-LOX in macrophage 
polarization requires better characterization.  The inhibition of human 12-LOX, by use of small 
molecule inhibitors, in early T1D may therefore represent a powerful approach to intervening in 
the early pathogenesis of the disease.  A challenge in the development of next-generation small 
molecule inhibitors, however, lies in structural and functional differences between mouse and 
human enzymes.  These differences limit testing of human-specific inhibitors in mouse 
preclinical models.  Therefore, rather than inhibiting 12/15-LOX action directly, it may be more 
beneficial to block receptors, such as the G-protein-coupled receptor GPR31, which bind to pro-
inflammatory ligands that are products of 12/15-LOX (Guo, Y et al., 2011; Zhang et al., 2018).  
This approach could represent a new avenue to overcome specificity effects of inhibitors 
targeting different 12/15-LOX isoforms.  In addition, development of humanized mouse models 
in which the mouse 12/15-LOX is replaced by human 12-LOX would help test new small 
molecule 12-LOX inhibitors in mouse models of diabetes.  Given that there are only limited 
concerns in treating with globally administered 12-LOX inhibitors, this appears to be a viable 
treatment target that should be pursued.  We cannot conclude this chapter before fully 
acknowledging that, while we focused on the 12-LOX pathway on pathogenesis of diabetes and 
complications, other lipid mediators such as lysophosphatidic acids, diacylglycerols, ceramides, 
and sphingosines, play significant roles in inflammatory processes responsible for onset and 
progression of type 1 and type 2 diabetes. Concerted efforts and expertise from various 
investigators are therefore granted to fully understand the role of various lipid classes in 
inflammation and metabolic diseases and to find the most instrumental approaches for new 
therapeutic interventions. 
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Table 1. Description of LOX Isoforms Discussed in This Review 
 
Lipoxygenase 
Protein Name 
Human 
Gene 
Mouse 
Gene 
Products Forms from AA 
Metabolism 
Term Used in This 
Review 
Leukocyte-type 12-
LOX (15-LOX1 for 
human, 12/15-LOX 
for mouse 
ALOX15 Alox15 
Human protein produces 
10% 12(S)-HETE/90% 
15(S)-HETE; Mouse 
protein produces 90% 
12(S)-HETE/10% 15(S)-
HETE 
12/15-LOX 
Platelet-type 12-
LOX 
ALOX 12 Alox12 Human and mouse 
proteins are functionally 
similar, and produce 
12(S)-HETE 
12-LOX 
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Figure legends 
 
Figure 1.  Selective human 12-LOX inhibitors and human 12/15-LOX dual inhibitor. Shown 
are the structures of selective human 12-LOX inhibitors: 0-hydroxyquinoline-based ML127 and 
N-(benzo[d]thiazol-2-yl)-4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide  ML355. 
Also shown is the 12/15-LOX dual inhibitor ML351, which is an amine oxazol.  
 
Figure 2.  Role of 12-LOX and metabolites in beta cell demise.  The figure depicts the 
pathways activated by 12-LOX in the pancreatic islet beta cell in response to elevated glucose 
levels, saturated free fatty acids, or PIC.  12-LOX activation leads to the production of pro-
inflammatory lipid intermediates (12(S)-hydroperoxyeicosatetraenoic acid and 12(S)-HETE).  
These intermediates trigger subsequent inflammatory pathways mediated by c-Jun N-terminal 
kinase, p38-MAPK, and NOX.  12(S)-HETE prevents translocation of Nrf2 as well.  Signaling 
through these pathways leads to increased ROS, oxidative stress, ER stress, which eventually 
cause beta cell dysfunction and death. Although not depicted in this diagram, other lipid 
mediators such as LPA and LPC contribute to MCP-1 mediated chemotaxy; ceramides 
contribute to beta-cell death, etc. FFAR, free fatty acid receptor; PLA, phospholipase A2; PGE2, 
prostaglandin E2; MCP1, monocyte chemoattractant protein 1. 
 
Figure 3. The complex role of 12- and 15-LOX in exacerbation and resolution of adipose 
tissue inflammation. A) Excess consumption of energy demands an increased nutrient storage 
capacity of adipocytes in white adipose tissue (WAT).  As a result, adipocytes become 
hypertrophic and stressed, leading to dysfunction marked by ensuing inflammation.  Expression 
of pro-inflammatory cytokines, lipocalin-2 (LCN2), renin angiotensin system (RAS) markers, and 
ER stress markers by these stressed adipocytes and stromal vascular fraction (SVF) of the 
WAT leads to chronic leukocyte-type 12-LOX (12/15-LOX) activation in the adipocyte and SVF 
and subsequent generation of pro-inflammatory lipid metabolites, such as 12(S)-HETE and 
15(S)-HETE.  12/15-LOX activity promotes further amplification of these pathways, in particular 
the interleukin-12 (IL-12) pathway.  This inflamed fat promotes the recruitment of macrophages 
and other inflammatory cells into the fat bed, further propagating the inflammatory autocrine 
cascade.  In addition, WAT exerts paracrine and endocrine pro-inflammatory effects through 
secreted cytokines on various organ systems, including the pancreas, liver, and vasculature, 
leading to metabolic decline.  B) Diets enriched in ω-3 fatty acids or acute inflammatory 
responses acutely activate the 12- and 15-LOX enzymes in normal or inflamed hypertrophic 
WAT to generate anti-inflammatory or pro-resolving lipid metabolites, such as the maresins, 
resolvins, protectins, and lipoxins.  Thereby targeting 12/15-LOX activity may be a novel 
therapeutic target in treating Local WAT and systemic metabolic dysfunction. 
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Figure 1.  Selective human 12-LOX inhibitors (ML355 and ML127) and 
human 12/15-LOX inhibitor ML351 
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Figure 2. Role of 12-LOX and metabolites in beta cell demise 
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Figure 3. The complex role of 12- and 15-LOX in exacerbation and 
resolution of adipose tissue inflammation  
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